Lancet Respiratory Medicine

Papers
(The H4-Index of Lancet Respiratory Medicine is 92. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Postoperative CPAP after major abdominal surgery846
Time to move away from an oxygen-centric model of pulmonary infarction?566
Concerns regarding a suggested long COVID paradigm – Authors' reply487
European Respiratory Society International Congress 2022446
Video laryngoscopy is not the nemesis of direct laryngoscopy396
Major gaps in childhood pneumonia research priorities remain312
The course of action for effective anti-cytokine treatment in COVID-19311
Correction to Lancet Respir Med 2024; 12: 129–40293
Correction to Lancet Respir Med 2019; 7: 745–56288
Rituximab for connective tissue disease-associated interstitial lung disease275
Savolitinib in NSCLC: progress in the MET exon 14 journey241
Broad protection from SARS-CoV-2 variants without antigen matching233
GOLD report: 2022 update228
Why has the incidence of tuberculosis not reduced in London during the COVID-19 pandemic?221
Predatory publishers appear in PubMed (and your inbox)219
Predicted bodyweight—a misleading metric for tidal volume titration?211
Australia bans engineered stone to prevent silicosis206
Long COVID: systemic inflammation and obesity as therapeutic targets194
The burden of tuberculosis in Libya193
Predictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study177
Eat or heat: fuel poverty and childhood respiratory health176
Thoracentesis: an old story and some new sources176
Interstitial lung disease: a decade of progress and hope175
Chronic obstructive pulmonary disease: 10 years of precision-guided success173
Use of fibrinolytics and deoxyribonuclease in adult patients with pleural empyema: a consensus statement168
Opioids bring peace to patients with IPF cough167
Impact of Myanmar's earthquake on respiratory health167
FLiRTing with danger as SARS-CoV-2 variants evolve164
European Society of Intensive Care Medicine (ESICM) LIVES 35th Annual Congress156
US Senate committee investigates asthma inhaler prices156
Risk factors for COVID-19-associated pulmonary aspergillosis: a systematic review and meta-analysis154
Top ten research priorities for breathlessness research: UK James Lind Alliance priority setting partnership154
Optimising trial design for cardiogenic shock: insights from the sixth Critical Care Clinical Trialists Workshop154
One-off low-dose CT for lung cancer screening in China: a multicentre, population-based, prospective cohort study153
Concerns about PRISm150
First results from the international paediatric bronchiectasis registry (Child-BEAR-Net Registry) describing multicountry variations in childhood bronchiectasis and its management: a multicentre, cros149
Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials148
Bedaquiline, pretomanid, and linezolid with or without moxifloxacin for tuberculosis147
Advancing precision medicine for acute respiratory distress syndrome146
Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial140
Sarcoidosis and fatigue: there is a useful cognitive treatment? – Authors' reply139
Cytokine adsorption and ECMO in patients with COVID-19139
Genetic associations and lung function in IPF: unexpected answers, persistent questions139
Claudio Castanos—leader in cystic fibrosis care in Argentina137
Priorities for NICE in health and social care135
US EPA signals renewed regulatory scrutiny of toxic air pollution134
Solid and semi-solid perspectives in thoracic surgery133
Challenges of modulating the risk of bronchopulmonary dysplasia in clinical trials132
Overcoming barriers to scaling up tuberculosis preventive treatment for household contacts130
Correction to Lancet Respir Med 2025; 13: 244–55129
Nasally delivered SARS-CoV-2 vaccines: future promise and challenges128
Correction to Lancet Respir Med 2022; 10: 972–84128
Correction to Lancet Respir Med 2021; 9: 1275–87127
Health effects of gas fuels: interpreting evidence from a comprehensive meta-analysis125
Patient with cystic fibrosis not diagnosed until age 23 years now treated with the new triple therapy Trikafta125
Vaccination in the world's top athletes125
Perioperative lung expansion and pulmonary outcomes after open abdominal surgery versus usual care in the USA (PRIME-AIR): a multicentre, randomised, controlled, phase 3 trial124
Preoxygenation strategies for intubation of patients who are critically ill: a systematic review and network meta-analysis of randomised trials122
Improving lifelong respiratory health after preterm birth120
Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysis120
Chronic cough as a disease: implications for practice, research, and health care118
Comparative vaccine effectiveness against severe COVID-19 over time in US hospital administrative data: a case-control study117
Awake prone positioning in COVID-19: is tummy time ready for prime time?116
Transbronchial cryobiopsy followed by as-needed surgical lung biopsy versus immediate surgical lung biopsy for diagnosing interstitial lung disease (the COLD study): a randomised controlled trial116
Evaluation of the effect of multimorbidity on difficult-to-treat asthma using a novel score (MiDAS): a multinational study of asthma cohorts116
Endoscopic sinus surgery with medical therapy versus medical therapy for chronic rhinosinusitis with nasal polyps: a multicentre, randomised, controlled trial116
Lung epithelial and myeloid innate immunity in influenza-associated or COVID-19-associated pulmonary aspergillosis: an observational study115
Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial115
Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial110
Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis110
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, co109
Trump administration decimates worker health oversight109
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CRO109
Effectiveness of preventive treatment among different age groups and Mycobacterium tuberculosis infection status: a systematic review and individual-participant data meta-analysis of contact tracing s108
Extracorporeal cardiopulmonary resuscitation: not why, but how108
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, doub106
Nintedanib for treating progressive fibrosing interstitial lung diseases106
Association of SARS-CoV-2 infection and persistence with long COVID106
Trouble with promoting lung cancer screening in never-smokers103
Ceftriaxone to prevent early ventilator-associated pneumonia in patients with acute brain injury: a multicentre, randomised, double-blind, placebo-controlled, assessor-masked superiority trial103
Venus and Mars: chest wall deformity and thoracic disease102
Determinants of long-term outcomes in patients with COVID-19 supported with ECMO102
COPD: a complex, multifactorial, but preventable disease?101
Underappreciated causes of obstructive lung disease101
Spirometry in female individuals – Authors' reply100
Correction to Lancet Respir Med 2023; 11: 1064–74100
Unveiling a hidden phenotype of early tuberculosis98
Health effects from climate-driven events: lessons learnt98
COP27 Climate Change Conference: urgent action needed for Africa and the world95
Developments and priorities in bronchiectasis research94
Liberal or restrictive transfusion for VV ECMO93
Realignment of clinical research after the COVID-19 era93
Opioid use and sleep apnoea92
Tackling tuberculosis: what lies beneath the surface?92
0.054630041122437